2sev­en­ty inks T cell part­ner­ship with Chi­nese biotech; An­ti­sense drug caus­es brain side ef­fect — re­port

2sev­en­ty bio has se­cured an I/O deal with a Chi­nese biotech.

The blue­bird bio spin­out, which formed last year, an­nounced a deal Thurs­day morn­ing with JW Ther­a­peu­tics to put to­geth­er a ther­a­py plat­form to speed up T cell-based im­munother­a­py prod­ucts for Chi­na, Macao and Hong Kong.

The ini­tial fo­cus of the col­lab­o­ra­tion is 2sev­en­ty bio’s TCR pro­gram called Mage-A4, which fo­cused on sol­id tu­mors and is cur­rent­ly be­ing de­vel­oped as part of a pre­vi­ous col­lab­o­ra­tion with Re­gen­eron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER